Elevance Health beat Wall Street’s Q2 earnings estimates by a wide margin on Wednesday, but the stock fell sharply as investors zeroed in on shrinking margins.
ELV dropped more than 9% in premarket trading after results hit the wire. The stock had been up nearly 22% in 2026 heading into results, closing at $426.79 on Monday.
Adjusted earnings per share came in at $7.45, clearing the analyst consensus of $6.21 by $1.24. Revenue reached $49.8 billion, up 0.8% year-over-year and above the $48.63 billion estimate.
ELEVANCE HEALTH $ELV Q2’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $49.8B (Est. $48.6B) 🟢; +0.8% YoY
🔹 Adj. EPS: $7.45 (Est. $6.18) 🟢; -15.7% YoY
🔹 Benefit Expense Ratio: 89.7% (Est. 89.4%) 🔴; +80 bps YoYRaises FY26 Guide:
🔹 Diluted EPS: at least $20.10
🔹 Adj. EPS: at least…— Wall St Engine (@wallstengine) July 15, 2026
The beat wasn’t enough to satisfy the market. Operating margin dropped to 3.5% from 4.9% in the same quarter last year. The adjusted operating margin also slipped, falling to 3.6% from 5.0%.
Inside the core Health Benefits segment, the picture was sharper. Operating margin there fell to 2.1% from 3.8% a year ago.
The benefit expense ratio rose 80 basis points year-over-year to 89.7%. Elevated medical costs in government programs drove that increase, though better Individual ACA performance helped offset some of the pressure.
Elevance raised its full-year adjusted EPS guidance to at least $27.00, up from at least $26.75 previously. That sits just above the analyst consensus of $26.91. Operating cash flow guidance was also lifted to at least $6.0 billion.
This marks the second guidance hike in months. The company raised its outlook in April and reiterated it again in June.
CEO Gail Boudreaux said results “exceeded our outlook, supported by disciplined execution and improved operating performance across our diversified portfolio.”
Medical membership stood at approximately 44.9 million as of June 30, 2026, down 469,000 from the prior quarter. The decline was tied to a commercial fee-based customer transition and expected attrition in Individual ACA and Medicaid membership.
The Health Benefits segment brought in $42.7 billion in revenue, up 3% year-over-year. Carelon revenue grew 6% to $19.2 billion.
Analysts had been broadly upbeat heading into the print. TD Cowen’s Ryan Langston raised his Elevance price target from $400 to $465 on Tuesday. Cantor Fitzgerald also lifted its target from $400 to $450.
Medicaid margins remain a watch point. CFO Mark Kaye said at a Goldman Sachs healthcare conference in June that costs in that segment stayed elevated, with a full-year margin target around -1.75%.
UBS analyst A.J. Rice had called that target “conservative,” suggesting there could be room for improvement.
Elevance reports a day before UnitedHealth Group, the largest player in the sector, which is set to post results Thursday.
The post Elevance Health (ELV) Stock Falls 9% After Earnings Beat — Here’s Why appeared first on CoinCentral.
